Jay Bradner (Jeff Rumans for Endpoints News)

Div­ing deep­er in­to in­her­it­ed reti­nal dis­or­ders, No­var­tis gob­bles up an­oth­er bite-sized op­to­ge­net­ics biotech

Right about a year ago, a No­var­tis team led by Jay Brad­ner and Cyn­thia Grosskreutz at NI­BR swooped in to scoop up a Cam­bridge, MA-based opthal­mol­o­gy gene ther­a­py com­pa­ny called Vedere. Their fo­cus was on a spe­cif­ic mar­ket niche: in­her­it­ed reti­nal dy­s­tro­phies that in­clude a wide range of ge­net­ic reti­nal dis­or­ders marked by the loss of pho­tore­cep­tor cells and pro­gres­sive vi­sion loss.

But that was just the first deal that whet their ap­petite.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.